Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2021

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
This study aimed to investigate the impact of intensive cholesterol-lowering therapy (including evolocumab), drug treatment for high-risk plaques (Vulnerable plaques) with a high probability of developing acute coronary syndrome. The purpose of this study is to determine the effect of the change in the Lipid core burden index and compare the rate of cardiac events over 12 months following cholesterol therapy.
Epistemonikos ID: 9908e08f7d221819a7eddf733972485a8dc3c2f7
First added on: May 08, 2024